Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 6/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080980 | 0.88 | NOD1 (0.43) | NOD1RAB9AMAPTNPSR1ALDH1A1 | |
| SCHEMBL3228662 | 0.84 | NOD1 (0.42) | NOD1DPP7HTR2C | |
| SCHEMBL2120818 | 0.84 | NOD1 (0.44) | NOD1HTR2CACHE | |
| SCHEMBL27812060 | 0.82 | NOD1 (0.46) | NOD1NPSR1HTR2CACHE | |
| SCHEMBL27631472 | 0.79 | L3MBTL1 (0.34) | NOD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28223725 | 0.78 | NOD1 (0.47) | NOD1NPSR1HTR2CACHE | |
| SCHEMBL20511491 | 0.77 | GGT1 (0.50) | NOD1ALDH1A1 | |
| SCHEMBL468919 | 0.76 | NOD1 (0.45) | NOD1RAB9AMAPTNPSR1ALDH1A1 | |
| SCHEMBL468917 | 0.76 | NOD1 (0.45) | NOD1RAB9AMAPTNPSR1ALDH1A1 | |
| SCHEMBL28337313 | 0.76 | NOD1 (0.43) | NOD1DPP7HTR2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-10-25 | — | — | US | claimed |
| WO-2018176065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-09-27 | — | — | WO | claimed |
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | OREGON STATE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-10-25 | — | — | US | disclosed |
| WO-2018176065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | TNNC1, PYGM, MYLK2 | NOD1 4770/4885RAB9A 2300/4885MAPT 2838/4885 |
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | TNNC1, PYGM, MYLK2 | NOD1 4770/4885RAB9A 2300/4885MAPT 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.